Physician profile
Emily Brumfield
NPI 1013103613
$13,764.66
in general payments reported to CMS, 2019-2025
43 companies · $3,315 in 2025
The $3,315 reported for 2025 was more than what 98% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,604 · 2022: $2,516 · 2023: $1,581 · 2024: $3,749 · 2025: $3,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,375 · Food and Beverage: $3,466 · Consulting Fee: $675 · Travel and Lodging: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,375.00 |
| Food and Beverage | $3,465.82 |
| Consulting Fee | $675.00 |
| Travel and Lodging | $128.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $5,503.13 | 2021-2025 | Xcopri |
| Pfizer INC. | $1,440.54 | 2023-2025 | |
| Abbvie INC. | $694.57 | 2021-2025 | |
| Ucb, INC. | $476.07 | 2021-2025 | Nayzilam, Fintepla, Briviact |
| Avanir Pharmaceuticals, INC. | $472.30 | 2021-2022 | |
| Amgen INC. | $416.52 | 2021-2023 | Aimovig |
| Acadia Pharmaceuticals INC | $408.79 | 2021-2023 | Nuplazid |
| Biohaven Pharmaceutical Holding Company Ltd. | $373.12 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $350.27 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $331.82 | 2021 | |
| Allergan, INC. | $258.89 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $225.66 | 2021-2023 | Ponvory |
| Eisai INC. | $218.82 | 2021-2022 | |
| Genzyme Corporation | $201.36 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $191.38 | 2021-2023 | Ongentys, Ingrezza |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $181.24 | 2021-2025 | Wainua |
| Lundbeck LLC | $179.44 | 2022-2025 | Vyepti |
| Genentech USA, INC. | $179.24 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Emd Serono, INC. | $167.38 | 2021-2025 | Mavenclad |
| Axsome Therapeutics, INC. | $159.24 | 2025 | Symbravo |
| Acorda Therapeutics, INC | $133.60 | 2021-2023 | Inbrija |
| Otsuka America Pharmaceutical, INC. | $133.54 | 2023 | Nuedexta |
| Mdd US Operations, LLC | $130.99 | 2022-2023 | Apokyn, Xadago |
| Alexion Pharmaceuticals, INC. | $122.11 | 2021-2023 | Ultomiris |
| Horizon Therapeutics Plc | $101.80 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $99.25 | 2023 | Relyvrio |
| Kyowa Kirin, INC. | $85.64 | 2021-2023 | Nourianz |
| Axogen | $80.85 | 2023 | Avance Nerve Graft |
| Sunovion Pharmaceuticals INC. | $71.07 | 2021 | |
| Lilly USA, LLC | $62.30 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $61.74 | 2023-2025 | Purified Cortrophin Gel |
| Argenx US, INC. | $41.21 | 2022 | |
| Biogen, INC. | $32.65 | 2023 | Tysabri, Vumerity |
| Alnylam Pharmaceuticals INC. | $28.42 | 2022-2023 | Onpattro |
| Novartis Pharmaceuticals Corporation | $25.20 | 2023 | |
| Merz Pharmaceuticals, LLC | $23.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.92 | 2021 | |
| Ge Healthcare | $16.63 | 2022 | |
| Neurelis, INC. | $16.28 | 2023 | Valtoco |
| Boston Scientific Corporation | $15.24 | 2021 | |
| Ns Pharma, INC. | $12.79 | 2022 | |
| Amneal Pharmaceuticals LLC | $11.78 | 2022 | |
| Upsher-Smith Laboratories LLC | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Brumfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.